Pharmaceutical

The changing of the guard is expected in the Crohn’s disease marketplace

As per GlobalData, AbbVie has remained the Crohn’s disease market leader over the last five years, with Humira sales of $2.7bn in 2022 in 8MM.

Sep 1, 2023 - 20:00
The changing of the guard is expected in the Crohn’s disease marketplace
As per GlobalData, AbbVie has remained the Crohn’s disease market leader over the last five years, with Humira sales of $2.7bn in 2022 in 8MM.
Read the original article

Tags:

Previous Article

Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

Next Article

Reset Pharma partners with Filament to license psilocybin drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Patients loved Carbon Health’s diabetes program. That couldn’t save it

STAT+: Patients loved Carbon Health’s diabetes program....

Nov 13, 2023

STAT+: Banning surprise medical bills is raising costs elsewhere

STAT+: Banning surprise medical bills is raising costs ...

Feb 17, 2024

Here’s why obesity grew so quickly worldwide, and where that’s starting to change

Here’s why obesity grew so quickly worldwide, and where...

Jun 8, 2023